Lead Optimization in Discovery Drug Metabolism and Pharmacokinetics/Case study: The Hepatitis C Virus (HCV) Protease Inhibitor SCH 503034

Por Cheng, K.-C., Korfmacher, Walter A., White, Ronald E., Njoroge, F. George
Publicado em 2007

Meeting Report: Metabolites in Safety Testing (MIST) Symposium—Safety Assessment of Human Metabolites: What’s REALLY Necessary to Ascertain Exposure Coverage in Safety Tests?

Por Gao, Hongying, Jacobs, Abigail, White, Ronald E., Booth, Brian P., Obach, R. Scott
Publicado em 2013

Interactions between Penicillin-Binding Proteins (PBPs) and Two Novel Classes of PBP Inhibitors, Arylalkylidene Rhodanines and Arylalkylidene Iminothiazolidin-4-ones

Por Zervosen, Astrid, Lu, Wei-Ping, Chen, Zhouliang, White, Ronald E., Demuth, Thomas P., Frère, Jean-Marie
Publicado em 2004

Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders

Por Gurney, Mark E., Nugent, Richard A., Mo, Xuesheng, Sindac, Janice A., Hagen, Timothy J., Fox, David, O’Donnell, James M., Zhang, Chong, Xu, Ying, Zhang, Han-Ting, Groppi, Vincent E., Bailie, Marc, White, Ronald E., Romero, Donna L., Vellekoop, A. Samuel, Walker, Joel R., Surman, Matthew D., Zhu, Lei, Campbell, Robert F.
Publicado no J Med Chem (2019)